Cover Image
市場調查報告書

高雪氏症:開發中產品分析

Gaucher Disease - Pipeline Review, H1 2016

出版商 Global Markets Direct 商品編碼 363112
出版日期 內容資訊 英文 78 Pages
訂單完成後即時交付
價格
Back to Top
高雪氏症:開發中產品分析 Gaucher Disease - Pipeline Review, H1 2016
出版日期: 2016年06月15日 內容資訊: 英文 78 Pages
簡介

本報告提供高雪氏症治療藥的開發情形相關資訊,提供您各開發階段,藥物標的,作用機制,給藥途徑及分子類型別分析,開發治療藥的企業概要,最新消息和新聞稿等資訊。

簡介

  • 調查範圍

高雪氏症概要

治療藥的開發

  • 開發中產品的概要
  • 開發中產品比較分析

高雪氏症:企業開發中的治療藥

高雪氏症:大學/機關研究中的治療藥

高雪氏症:開發中產品概況

  • 臨床階段的產品
  • 初期階段的產品

高雪氏症:企業開發中的產品

高雪氏症:大學/機關研究中的產品

高雪氏症治療藥的開發企業

  • Actelion Ltd
  • Bioorganic Research and Services S.A.
  • Genzyme Corporation
  • greenovation Biotech GmbH
  • JCR Pharmaceuticals Co., Ltd.
  • Lixte Biotechnology Holdings, Inc.
  • Neuraltus Pharmaceuticals, Inc.
  • Okklo Life Sciences BV
  • Pharming Group N.V.
  • Protalix BioTherapeutics, Inc.
  • Sangamo BioSciences, Inc.
  • Shire Plc
  • The International Biotechnology Center (IBC) Generium

高雪氏症:治療藥的評估

  • 單劑產品
  • 標的別
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

藥物簡介

高雪氏症:暫停中的計劃

高雪氏症:中止開發的產品

高雪氏症:產品開發的里程碑

  • 主要消息和新聞稿

附錄

目錄
Product Code: GMDHC8179IDB

Summary

Global Markets Direct's, 'Gaucher Disease - Pipeline Review, H1 2016', provides an overview of the Gaucher Disease pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Gaucher Disease, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Gaucher Disease and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Gaucher Disease
  • The report reviews pipeline therapeutics for Gaucher Disease by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved Gaucher Disease therapeutics and enlists all their major and minor projects
  • The report assesses Gaucher Disease therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news related to pipeline therapeutics for Gaucher Disease

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Gaucher Disease
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Gaucher Disease pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
    • Gaucher Disease Overview
  • Therapeutics Development
    • Pipeline Products for Gaucher Disease - Overview
    • Pipeline Products for Gaucher Disease - Comparative Analysis
  • Gaucher Disease - Therapeutics under Development by Companies
  • Gaucher Disease - Therapeutics under Investigation by Universities/Institutes
  • Gaucher Disease - Pipeline Products Glance
    • Clinical Stage Products
    • Early Stage Products
  • Gaucher Disease - Products under Development by Companies
  • Gaucher Disease - Products under Investigation by Universities/Institutes
  • Gaucher Disease - Companies Involved in Therapeutics Development
    • Actelion Ltd
    • Bioorganic Research and Services S.A.
    • Genzyme Corporation
    • greenovation Biotech GmbH
    • JCR Pharmaceuticals Co., Ltd.
    • Lixte Biotechnology Holdings, Inc.
    • Neuraltus Pharmaceuticals, Inc.
    • Okklo Life Sciences BV
    • Pharming Group N.V.
    • Protalix BioTherapeutics, Inc.
    • Sangamo BioSciences, Inc.
    • Shire Plc
    • The International Biotechnology Center (IBC) Generium
  • Gaucher Disease - Therapeutics Assessment
    • Assessment by Monotherapy Products
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Drug Profiles
    • ambroxol - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • BNT-001 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ibiglustat - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • imiglucerase biosimilar - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • LB-201 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • LB-205 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • miglustat - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • MOSS-GBA - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • NP-003 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • OKL-1014 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • PRX-112 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Recombinant Beta Glucosidase 2 Replacement for Gaucher's Disease and Male Infertility - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Recombinant Beta-Cerebrosidase Replacement for Gaucher's Disease - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • SBLSD-3 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecule to Activate Beta-Galactosidase for GM1 Gangliosidosis and Gaucher's disease - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecule to Activate Glucocerebrosidase for Parkinson's, Gaucher's and Neurodegenerative Diseases - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules to Activate Glucocerebrosidase for Gaucher and Parkinson Disease - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules to Inhibit Glucosidase for Diabetes and Gaucher's Disease - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • taliglucerase alfa - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • velaglucerase alfa - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Gaucher Disease - Dormant Projects
  • Gaucher Disease - Discontinued Products
  • Gaucher Disease - Product Development Milestones
    • Featured News & Press Releases
      • Sep 02, 2014: Shire's VPRIV400 units/vial launched in Japan for the improvement of symptoms of Gaucher disease
      • Jul 04, 2014: Shire's VPRIV approved in Japan for the improvement of symptoms of Gaucher disease
      • Jun 18, 2014: Protalix BioTherapeutics Initiates Phase II Study With PRX-112, an Orally-Administered Enzyme Replacement Therapy for the Treatment of Gaucher Disease
      • Mar 14, 2014: Shire Pharmaceuticals Initiates Voluntary Nationwide Recall Of One Batch, Packaged into Three Lots, of VPRIV (velaglucerase alfa for injection)
      • Feb 14, 2014: Shire Announces FDA Approval of Manufacturing Facility for VPRIV (Velaglucerase Alfa for Injection) Drug Substance
      • Feb 12, 2014: Protalix BioTherapeutics Announces Oral GCD Data to be Presented at WORLD Symposium 2014
      • Oct 14, 2013: Protalix BioTherapeutics Announces Positive Phase I Clinical Trial Results for Oral GCD in Gaucher Disease Patients
      • Apr 02, 2013: Protalix BioTherapeutics Treats First Gaucher Patient In Phase I Study With PRX-112
      • Mar 07, 2013: Protalix BioTherapeutics Receives Approval From Israeli Ministry Of Health To Initiate Phase I Clinical Trial Of PRX-112 For Treatment Of Gaucher Disease
      • Jun 28, 2012: Shire's Vpriv Shows Significant Improvement In Gaucher-Related Bone Disease
      • Jun 28, 2012: Shire's Vpriv Shows Significant Improvement In Gaucher-Related Bone Disease
      • Feb 22, 2012: Shire Announces European Approval Of Manufacturing Facility For VPRIV
      • Dec 19, 2011: Lixte's LB-205 Shows Therapeutic Potential For Gaucher Disease
      • Nov 22, 2011: Shire Announces Regulatory Filings In US And EU For New Manufacturing Facility
      • Mar 21, 2011: Shire Presents Data For VPRIV In Gaucher Disease At 2011 ACMG Annual Meeting
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Gaucher Disease, H1 2016
  • Number of Products under Development for Gaucher Disease - Comparative Analysis, H1 2016
  • Number of Products under Development by Companies, H1 2016
  • Number of Products under Investigation by Universities/Institutes, H1 2016
  • Comparative Analysis by Clinical Stage Development, H1 2016
  • Comparative Analysis by Early Stage Development, H1 2016
  • Products under Development by Companies, H1 2016
  • Products under Investigation by Universities/Institutes, H1 2016
  • Gaucher Disease - Pipeline by Actelion Ltd, H1 2016
  • Gaucher Disease - Pipeline by Bioorganic Research and Services S.A., H1 2016
  • Gaucher Disease - Pipeline by Genzyme Corporation, H1 2016
  • Gaucher Disease - Pipeline by greenovation Biotech GmbH, H1 2016
  • Gaucher Disease - Pipeline by JCR Pharmaceuticals Co., Ltd., H1 2016
  • Gaucher Disease - Pipeline by Lixte Biotechnology Holdings, Inc., H1 2016
  • Gaucher Disease - Pipeline by Neuraltus Pharmaceuticals, Inc., H1 2016
  • Gaucher Disease - Pipeline by Okklo Life Sciences BV, H1 2016
  • Gaucher Disease - Pipeline by Pharming Group N.V., H1 2016
  • Gaucher Disease - Pipeline by Protalix BioTherapeutics, Inc., H1 2016
  • Gaucher Disease - Pipeline by Sangamo BioSciences, Inc., H1 2016
  • Gaucher Disease - Pipeline by Shire Plc, H1 2016
  • Gaucher Disease - Pipeline by The International Biotechnology Center (IBC) Generium, H1 2016
  • Assessment by Monotherapy Products, H1 2016
  • Number of Products by Stage and Target, H1 2016
  • Number of Products by Stage and Mechanism of Action, H1 2016
  • Number of Products by Stage and Route of Administration, H1 2016
  • Number of Products by Stage and Molecule Type, H1 2016
  • Gaucher Disease - Dormant Projects, H1 2016
  • Gaucher Disease - Dormant Projects (Contd..1), H1 2016
  • Gaucher Disease - Discontinued Products, H1 2016

List of Figures

  • Number of Products under Development for Gaucher Disease, H1 2016
  • Number of Products under Development for Gaucher Disease - Comparative Analysis, H1 2016
  • Number of Products under Development by Companies, H1 2016
  • Number of Products under Investigation by Universities/Institutes, H1 2016
  • Comparative Analysis by Clinical Stage Development, H1 2016
  • Comparative Analysis by Early Stage Products, H1 2016
  • Assessment by Monotherapy Products, H1 2016
  • Number of Products by Targets, H1 2016
  • Number of Products by Stage and Targets, H1 2016
  • Number of Products by Mechanism of Actions, H1 2016
  • Number of Products by Stage and Mechanism of Actions, H1 2016
  • Number of Products by Routes of Administration, H1 2016
  • Number of Products by Stage and Routes of Administration, H1 2016
  • Number of Products by Molecule Types, H1 2016
  • Number of Products by Stage and Molecule Types, H1 2016
Back to Top